Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;28(5):895-896.
doi: 10.1002/lt.26416. Epub 2022 Feb 24.

Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation

Zhe Yang  1 , Jingqi Sun, Li Zhuang, Haibo Mou, Shusen Zheng
Affiliations

Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation

Zhe Yang et al. Liver Transpl. 2022 May.
No abstract available

PubMed Disclaimer

Comment in

References

    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T‐Y, et al.; IMbrave150 Investigators . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–1905.
    1. Ben Khaled N, Roessler D, Reiter FP, Seidensticker M, Guba M, De Toni EN. Extending the use of atezolizumab and bevacizumab to a liver transplant recipient: need for a posttransplant registry. Liver Transpl 2021;27:928–929.
    1. Abdel‐Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019;7:106.
    1. Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J 2018;6:970–973.

Publication types

MeSH terms